Arrowhead Pharmaceuticals (ARWR) Stock Forecast & Price Target

Arrowhead Pharma is positioned favorably because its core RNAi platform is showing real clinical de-risking in both CNS and cardiometabolic markets, with ARO-MAPT producing up to 73% mean CSF total tau reduction at Day 105 and plozasiran delivering 79% to 81% median triglyceride reductions at Month 12. The company’s safety profile also looks supportive, with no serious TEAEs in the ARO-MAPT healthy-volunteer dataset and clean SHASTA-3/-4 safety readouts, while the disclosed ~215 million PRV and targeted sNDA before year-end 2026 strengthen the path to commercialization. Beyond single-asset wins, management is building a broader franchise with at least four additional CNS clinical entrants overall by end-2027, which adds platform value and multiple shots on goal.

Arrowhead Pharma is facing a fundamental bearish case because its continuing cash burn may force it to raise additional debt or equity, with the risk that financing could be unavailable or materially dilutive to stockholders. The company’s RNAi pipeline also carries substantial execution risk, as products could fail to meet clinical endpoints, regulators may narrow approved indications, and the TRIM delivery technology is still being tested in multiple human clinical studies. On top of that, its patents may not fully protect key assets, while intense competition from better-resourced biotech and pharmaceutical rivals could erode the commercial value of its therapies if alternative treatments advance more quickly.